Uncontrolled inflammatory response highlights the central theme of nonalcoholic steatohepatitis (NASH), a growing global pandemic. Hepatocytes and macrophages represent two major sources of hepatic inflammation during NASH pathogenesis, contributing to excessive synthesis of proinflammatory mediators. The epigenetic mechanism that accounts for the activation of hepatocytes and macrophages in this process remains obscure. Here, we report that compared to wild-type littermates, mice with a deficiency in the histone H3K9 methyltransferase suppressor of variegation 39 homolog 2 (Suv39h2, knockout) exhibited a less severe form of NASH induced by feeding with a high-fat, high-carbohydrate diet. Pro-NASH stimuli increased Suv39h2 expression in cell culture, in mice, and in human livers. In hepatocytes, Suv39h2 bound to the Sirt1 gene promoter and repressed Sirt1 transcription. Suv39h2 deficiency normalized Sirt1 expression, allowing nuclear factor kappa B/p65 to become hypoacetylated and thus dampening nuclear factor kappa B-dependent transcription of proinflammatory mediators. In macrophages, Suv39h2-mediated repression of peroxisome proliferator-activated receptor gamma transcription favored a proinflammatory M1 phenotype over an antiinflammatory M2 phenotype, thereby elevating hepatic inflammation. Conclusion: Suv39h2 plays a pivotal role in the regulation of inflammatory response in hepatocytes and macrophages, contributing to NASH pathogenesis. (HEPATOLOGY 2017;65:1904-1919.
N onalcoholic fatty liver disease (NAFLD) represents a prototypical human pathology acutely impacted by the external environment: high-fat, high-sugar diets combined with a lack of physical activity inevitably lead to a disruption of the normal metabolism in the liver. (1, 2) By definition, NAFLD encompasses a series of interconnected yet distinctive pathological stages that can, short of effective intervention, progress from simple steatosis to nonalcoholic steatohepatitis (NASH) to cirrhosis and hepatocellular carcinoma. (3) Despite decades of rigorous efforts dedicated to delineating the mechanisms underlying NAFLD, many critical questions remain unanswered. (4) Chronic inflammation is considered a major culprit for NAFLD progression, acting as a bridge linking simple steatosis to NASH. (5) Both hepatocytes and macrophages have been reported to contribute to hepatic inflammation in the context of NAFLD. Free fatty acids and high concentrations of glucose, for instance, are able to stimulate the production of a series of proinflammatory mediators including interleukin-1b (IL-1b, (6) IL-6, (7) IL-8, (8) and monocyte chemoattractant protein 1 (9) in hepatocytes. Excessive nutrient input has also been Abbreviations: ALT, alanine aminotransferase; BMDM, bone marrow-derived macrophage; CD, cluster of differentiation; ChIP, chromatin immunoprecipitation; HFD, high-fat, high-carbohydrate diet; IL, interleukin; KC, Kupffer cell; KO, knockout; LPS, lipopolysaccharide; LSD1, lysine-specific histone demethylase-1; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NF-jB, nuclear factor kappa B; PA, palmitate; PGC-1a, PPARc coactivator 1 alpha; PPARc, peroxisome proliferator-activated receptor gamma; Suv39h2, suppressor of variegation 39 homolog 2; WT, wild type.
shown to commit macrophages toward a classically activated (M1) phenotype while at the same time blocking the differentiation toward an alternatively activated (M2) phenotype, thus promoting hepatic inflammation. (10) A complex network of transcription factors, including nuclear factor kappa B (NF-jB) and peroxisome proliferatoractivated receptor gamma (PPARc), orchestrates these events in hepatic cells. (11) (12) (13) Transcriptional regulation in mammals is dictated by the epigenetic machinery, of which histone modifications constitute a key branch. (14) Suppressor of variegation 39 homolog 2 (Suv39h2) catalyzes histone H3 lysine 9 trimethylation and maintains the integrity of heterochromatin. (15) Suv39h2 knockout (KO) mice are viable, suggesting that Suv39h2 is dispensable for embryogenesis. (15) A recent epidemiological study has identified an association of SUV39H2 polymorphism with metabolic disorders in a Finnish population. (16) It remains largely enigmatic, however, whether Suv39h2 may regulate euchromatin-related transcription and contribute to postnatal pathophysiological processes. Here, we report that Suv39h2 deficiency protects mice from NASH. Specifically, Suv39h2 modulates hepatic inflammation by promoting the synthesis of hepatocytederived proinflammatory mediators and by programming macrophage polarization. Therefore, Suv39h2 could be considered a potential target for the development of novel therapeutic solutions against NASH.
Materials and Methods

ANIMALS
All animal protocols were approved by the Nanjing Medical University's Intramural Ethic Committee on Animal Studies. Suv39h2 KO mice and wild-type (WT) littermates have been described. (15) To induce NASH, 8-week-old male mice were fed a high-fat, high-carbohydrate diet (HFD; D12492; Research Diets) for 16 consecutive weeks. (17) 
HISTOLOGY
Histological analyses were performed essentially as described. (18, 19) Paraffin sections were stained with hematoxylin and eosin (Sigma) according to standard procedures. Parallel sections were stained for cell surface markers. Briefly, sections were blocked with 10% normal goat serum for 1 hour at room temperature and then incubated with anti-cluster of differentiation 68 (anti-CD68; Abcam) antibodies. Staining was visualized by incubation with antirabbit secondary antibody and developed with a streptavidin-horseradish peroxidase kit (Pierce) for 20 minutes. Pictures were taken using an Olympus IX-70 microscope. Frozen sections were stained with oil red O (Sigma) according to standard procedures. Slides were visualized on a confocal microscope (LSM 710; Zeiss). Quantifications were performed with Image J.
HUMAN SPECIMEN COLLECTION AND SUV39H2 STAINING
Liver biopsies were collected from patients with simple steatosis or NASH referred to the Affiliated Hospital of Nantong University. Control liver samples were collected from donors without NAFLD whose livers were deemed unsuitable for transplantation. Written informed consent was obtained from subjects or families of liver donors. All procedures that involved human samples were approved by the Ethics Committee of the Affiliated Hospital of Nantong University and adhered to the principles outlined in the Declaration of Helsinki. Basic information of the patients examined in this study is summarized in Supporting  Table S1 . To examine SUV39H2 expression, paraffin sections were stained with an anti-SUV39H2 antibody (GeneTex). Double-blind quantification was performed by two pathologists using ImagePro.
CELL CULTURE AND TREATMENT
Primary mouse hepatocytes, bone marrow-derived macrophages (BMDMs), and Kupffer cells (KCs) were isolated and maintained as described. (20) (21) (22) Macrophage differentiation was induced by the addition of lipopolysaccharide (LPS; 100 ng/mL), IL-4 (5 ng/ mL), palmitate (PA; 0.2 mM), or glucose (25 mM).
FLOW CYTOMETRY
Liver tissues were perfused with warm Hank's balanced salt solution (378C) containing collagenase IV and cut into small pieces with a sterile blade. The tissue suspension was filtered, washed, and centrifuged. Pellets were suspended with Roswell Park Memorial Institute 1640 medium and counted. Cells, 1 3 10 6 , were used for each reaction. Antibodies used for flow-cytometric analysis were fluorescein isothiocyanate-labeled anti-F4/80 (AbDSerotec), Alexa Flour 647-labeled anti-CD11c (eBioscience), and Alexa Flour 647-labeled anti-CD206 (eBioscience).
PROTEIN EXTRACTION AND WESTERN BLOT
Tissue and cell lysates were obtained as described. (23) Western blot analyses were performed with anti-SIRT1 (Abcam), anti-SUV39H2 (Proteintech), anti-acetyl lysine, anti-NF-jB (Cell Signaling), anti-PPARc (Santa Cruz), and anti-b-actin (Sigma) antibodies.
CHROMATIN IMMUNOPRECIPITATION
Chromatin immunoprecipitation (ChIP) assays were performed essentially as described. (7) Briefly, 100 lg formaldehyde crosslinked nuclear proteins were precipitated with anti-NF-jB, anti-PPARc coactivator 1 alpha (anti-PGC-1a; Santa Cruz), anti-PPARa (Proteintech), anti-acetyl H3K9, anti-trimethyl H3K9 (Millipore), and anti-SUV39H2 (Abcam). Precipitated genomic DNA was amplified by real-time PCR, with primers listed in Supporting Table S2 .
RNA ISOLATION AND REAL-TIME PCR
RNA was extracted with the RNeasy RNA isolation kit (Qiagen). Reverse-transcriptase reactions were performed using the SuperScript First-Strand Synthesis System (Invitrogen). Real-time PCRs were performed on an ABI Prism 7500 system. Primers and TaqMan probes used for real-time reactions were purchased from Applied Biosystems.
STATISTICAL ANALYSIS
Data are presented as mean 6 standard deviation. For experiments concerning multiple groups, one-way analysis of variance with post hoc Scheffe analyses were performed to evaluate the differences. The differences between two (control and experimental) groups were determined by two-sided, unpaired Student t test. P values <0.05 are considered significant.
Results
Suv39h2 DELETION IN MICE ATTENUATES NASH IN VIVO
We first assessed the role of Suv39h2 in NASH pathogenesis in an animal model. Suv39h2 KO mice and WT littermates were fed the HFD for 16 weeks to induce NASH. (17) Although WT and KO mice gained comparable weight when fed the HFD (Supporting Fig. S1A ), a set of measurements suggested that Suv39h2 deletion protected the mice from NASH-associated injuries. Alanine aminotransferase (ALT) levels (Fig. 1A) , plasma/liver triglyceride levels (Supporting Fig. S1B ), and plasma/ liver total cholesterol levels (Supporting Fig. S1C ) were lower in KO mice. The glucose tolerance test (Fig. 1B) and the insulin tolerance test (Fig. 1C) showed that KO mice maintained insulin sensitivity significantly better than WT mice. In addition, we observed, through histological staining, milder steatosis (hematoxylin and eosin staining), fewer inflammatory infiltrates (CD68 staining), and reduced lipid accumulation (oil red O staining) in the livers of Suv39h2 KO mice than WT mice The NAFLD activity score was evaluated by two independent pathologists. *P < 0.05, WT HFD versus KO HFD; **P < 0.01, WT HFD versus KO HFD; ***P < 0.001, WT HFD versus KO HFD. n 5 3 mice for the chow groups and n 5 6 mice for the HFD groups. Scale bar, 50 lm. Abbreviations: A.U., arbitrary units; AUC, area under the curve; GTT, glucose tolerance test; H&E, hematoxylin and eosin; ITT, insulin tolerance test. Immunoprecipitation was performed with anti-NF-jB/p65, and the precipitated immune complex (eluate) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blotting was performed with indicated antibodies. Of the starting material, 10% was included as input. Quantifications were performed using ImagePro based on three independent experiments. Abbreviations: Gapdh, glyceraldehyde 3-phosphate dehydrogenase; IB, immunoblotting; IgG, immunoglobulin G; IP, immunoprecipitation; Mcp1, monocyte chemoattractant protein 1. expression of such genes as Acc1, Elovl6, and Scd1, we found that there was an up-regulation of several genes responsible for fatty acid transport and oxidation including Cpt1 and Acox1 in Suv39h2 KO mice compared to WT mice (Supporting Fig.  S2A ). In accordance, ChIP assay confirmed that both PPARa and its cofactor PGC-1a, two key transcriptional factors of fatty acid oxidation, (24, 25) bound to the promoters of Cpt1 and Acox1 with enhanced affinity in the livers of Suv39h2 KO mice compared to WT mice (Supporting Fig. S2B ).
Quantitative PCR analyses confirmed that synthesis of proinflammatory mediators, including IL-1, IL-6, and monocyte chemoattractant protein 1, were dampened in KO mice compared to WT mice (Fig. 1E) . In addition, liver fibrogenesis induced by HFD feeding was attenuated in KO mice as evidenced by reduced expression of profibrogenic genes (e.g., Col1a1) and picrosirius staining of liver sections (Supporting Fig.  S3 ). Cumulatively, Suv39h2 mice were given a significantly lower NAFLD activity score as evaluated by two independent pathologists (Fig. 1F) . In aggregate, these data suggest that Suv39h2 deficiency might attenuate NASH in mice.
Suv39h2 IS UP-REGULATED BY PRO-NASH STIMULI IN VIVO AND IN VITRO
Next, we asked whether Suv39h2 expression could be stimulated in the liver during NASH pathogenesis. To this end, we examined hepatic Suv39h2 expression in an animal model of NASH. Indeed, Suv39h2 levels were up-regulated in the liver of C57/BL6 mice fed the HFD compared to those fed the control (chow) diet at both the mRNA ( Fig. 2A) and protein (Fig. 2B ) levels. Of key importance, we also found that there was a progressive increase of Suv39h2 expression, measured by immunohistochemical staining, in human liver specimens as the patients transitioned from steatosis to steatohepatitis (Fig. 2C) .
Then we probed the effect of free fatty acid (PA), a pro-NASH factor, on Suv39h2 expression in cultured hepatocytes and macrophages. We observed an elevation of Suv39h2 levels, both mRNA (Fig. 2D) and protein (Fig. 2E) , in primary mouse hepatocytes, BMDMs, and KCs, approximately 6-8 hours after exposure to PA. Thus, it appears that Suv39h2 levels are responsive to pro-NASH stimuli both in vivo and in vitro.
Suv39h2 DEFICIENCY SUPPRESSES PROINFLAMMATORY RESPONSE IN HEPATOCYTES
Hepatic inflammation, rooted in accelerated synthesis of proinflammatory mediators, plays a key role in hepatic insulin resistance and NASH pathogenesis.
(26) Therefore, we focused on the regulation of hepatic inflammation by Suv39h2. Hepatocytes have been indicated as a major source of NASH-associated inflammation in the liver. (27) We asked whether Suv39h2 could contribute to the synthesis of hepatocyte-derived proinflammatory cytokines. When exposed to PA, primary hepatocytes up-regulated the production of proinflammatory mediators including Il-1b, Il-6, and monocyte chemoattractant protein 1; Suv39h2 deficiency significantly dampened PA-induced transcription of proinflammatory mediators (Fig. 3A) . The master regulator of cellular inflammation, NF-jB, has been implicated in NASH pathogenesis, responsible for excessive nutrition-induced proinflammatory mediators. (28) Indeed, PA treatment markedly increased the binding of NF-jB to its target promoters as evidenced by ChIP assay (Fig. 3B) ; NF-jB bound to target promoter with higher affinity in WT hepatocytes than in Suv39h2 KO hepatocytes. ChIP assays performed using mouse liver homogenates confirmed the notion that in the absence of Suv39h2 there was a decrease in the NF-jB-target promoter interaction in vivo (Supporting Fig. S4A ).
It has been demonstrated that NF-jB activity is regulated by its posttranslational modifications. Specifically, deacetylation by the deacetylase SIRT1 inhibits NF-jB activity in the liver. (29) Therefore, we asked whether Suv39h2 could promote NF-jB deacetylation. PA treatment resulted in an increase in NF-jB acetylation in primary hepatocytes, consistent with enhanced binding activity of NF-jB (Fig. 3C) . Suv39h2 deletion, however, attenuated PA-induced NF-jB acetylation. Similarly, we found that there was a stronger increase in hepatic NF-jB acetylation in HFD-fed WT mice than Suv39h2 KO mice (Supporting Fig. S4B ). Together, these data suggest that Suv39h2 may regulate the transcription of proinflammatory mediators in hepatocytes, likely through translational modification of NF-jB activity.
Suv39h2 REPRESSES SIRT1 TRANSCRIPTION IN HEPATOCYTES
Once we observed a role for Suv39h2 in regulating NF-jB (de)acetylation through SIRT1, we were prompted to explore the possibility that Suv39h2 might do so by repressing SIRT1 transcription. ChIP assays revealed that in response to PA stimulation, Suv39h2 was recruited to the Sirt1 proximal promoter, but not to the glyceraldehyde 3-phosphate dehydrogenase promoter, in primary hepatocytes (Fig. 4A) . We also observed an increase in the association of Suv39h2 with the Sirt1 promoter, but not with the glyceraldehyde 3-phosphate dehydrogenase promoter, in the livers of HFD-fed mice compared to chow diet-fed mice (Supporting Fig. S5 ).
Of note, accompanying augmented Suv39h2 occupancy on the Sirt1 promoter, there was simultaneously an increase in histone H3K9 trimethylation (H3K9Me3) and a decrease in H3K9 acetylation (H3K9Ac) surrounding the same region both in vitro (Fig. 4A ) and in vivo (Supporting Fig. S5 ). PA treatment down-regulated Sirt1 expression in hepatocytes, but Suv39h2 deficiency partially overcame the repression (Fig. 4B,C) . In accordance, HFD feeding repressed hepatic Sirt1 expression much better in WT mice than in Suv39h2 KO mice (Supporting Fig.  S6A,B) . Recovery of Sirt1 expression in the absence of Suv39h2 paralleled the disappearance of H3K9Me3 and the accumulation of H3K9Ac surrounding the Sirt1 proximal promoter ( Fig. 4D; Supporting Fig.  S6C ). Taken together, these data suggest that Suv39h2-mediated repression of SIRT1 might be responsible for NF-jB-dependent proinflammatory transcription in hepatocytes.
Next, we examined whether the ability of Suv39h2 to regulate inflammation in hepatocytes relies on Sirt1. Pretreatment with a specific SIRT1 inhibitor, EX-527, completely abrogated the alleviation of proinflammatory mediator synthesis afforded by Suv39h2 deficiency (Fig. 5A) . Meanwhile, EX-527 also restored NF-jB binding activity in Suv39h2 KO hepatocytes, increasing its level comparable to that in WT hepatocytes (Fig. 5B) . In accordance, EX-527 treatment rescued acetylation of NF-jB/p65 in Suv39h2 KO cells (Fig. 5C ). Likewise, elimination of endogenous SIRT1 with small interfering RNA removed the brake on the expression of proinflammatory mediators and the binding of NF-jB/p65 to target promoters while preserving NF-jB/p65 acetylation status despite the absence of Suv39h2 (Fig. 5D-F) . Combined, we propose that Suv39h2 modulates NF-jB-dependent proinflammatory transcription in hepatocytes, at least in part by repressing SIRT1 expression.
Of interest, we found that while hepatocytes isolated from Suv39h2 KO mice expressed higher levels of Cpt1 and Acox1 than those isolated from WT mice, SIRT1 depletion with small interfering RNA (Supporting Fig.  S7A ) or inhibition with EX-527 (Supporting Fig. S8A ) abrogated the up-regulation. Likewise, augmented binding of PPARa and PGC-1a to the gene promoters in Suv39h2-deficient hepatocytes was also preempted by SIRT1 knockdown (Supporting Fig. S7B ) or pharmaceutical inhibition (Supporting Fig. S8B ), consistent with findings that suggest a role for SIRT1 in regulating the activities of PPARa and PGC-1a. (30) 
Suv39h2 DEFICIENCY SKEWS MACROPHAGE POLARIZATION
Macrophages represent another origin from which hepatic inflammation is derived during NASH pathogenesis. (31) It has been well documented that skewing of macrophages toward a proinflammatory M1 phenotype in lieu of an anti-inflammatory M2 phenotype contributes to NASH-associated inflammation. (32) Therefore, we evaluated the role of Suv39h2 in macrophage polarization. Quantitative PCR revealed that there was simultaneous down-regulation of M1 marker genes (e.g., CD11c and tumor necrosis factor-alpha) and up-regulation of M2 marker genes (e.g., CD206 and chitinase-like 3) in the livers of HFD-fed Suv39h2 KO mice compared to HFD-fed WT mice (Fig. 6A) 6B) . Next, we used a classic model of macrophage trans-differentiation to assess the role of Suv39h2 in this process. LPS-induced M1 differentiation was markedly suppressed in BMDMs and KCs isolated from Suv39h2 KO mice compared to WT mice; in contrast, IL-4 induced a more robust M2 commitment in h2 KO BMDMs/KCs than WT BMDMs/KCs (Fig.  6C) . Next, we used two NASH-relevant reagents, PA and high glucose (25 mM), to differentiate macrophages. Again, we found that Suv39h2 deficiency favored an M2 phenotype as PA (Fig. 6D) and glucose ( Fig. 6E) were less potent at stimulating M1 marker expression and suppressing M2 marker expression in h2 KO BMDMs/KCs. Therefore, we conclude that Suv39h2 might contribute to hepatic inflammation by influencing macrophage polarization.
Suv39h2 REPRESSES PPARc IN MACROPHAGES
We then tested the hypothesis that Suv39h2 might impact macrophage trans-differentiation by repressing PPARc, a transcription factor known to promote M2 differentiation while suppressing M1 differentiation. (33, 34) In response to three different stimuli-LPS (Supporting Fig. S9A ), PA ( to target promoters was examined by ChIP (B). Immunoprecipitation was performed with anti-NFjB/p65, and the precipitated immune complex (eluate) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blotting was performed with indicated antibodies. Of the starting material, 10% was included as input (C). Quantifications were performed using ImagePro based on three independent experiments. (D-F) Primary hepatocytes were isolated from WT or Suv39h2 KO mice and transfected with small interfering RNA, followed by exposure to PA (0.2 mM). Expression levels of proinflammatory mediators were examined by quantitative PCR (D). ChIP assay was performed with anti-NF-jB/p65 (E).
Immunoprecipitation was performed with anti-NF-jB/p65, and the precipitated immune complex (eluate) was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis.
Western blotting was performed with the indicated antibodies. Of the starting material, 10% was included as input (F). Quantifications were performed using ImagePro based on three independent experiments. Abbreviations: IB, immunoblotting; IP, immunoprecipitation; Mcp1, monocyte chemoattractant protein 1; SCR, scrambled; si, small interfering. LG, low gluclose; Nos2, nitric oxide synthase 2; Tnf-a, tumor necrosis factor alpha; Ym1, chitinase-like 3.
of Suv39h2 deletion in BMDMs/KCs mirrored the disappearance of H3K9Me3 and the reemergence of H3K9Ac on the Pparg promoter ( Fig. 7D; Supporting Figs. S9D and S10D), reaffirming that Pparg is a direct transcriptional target of Suv39h2. 
SIRT1 INHIBITION RESTORES INFLAMMATION IN Suv39h2-DEFICIENT MICE
Finally, we asked whether SIRT1 inhibition could effectively neutralize the protective effects of Suv39h2 deficiency and restore hepatic inflammation in mice. To this end, WT or Suv39h2 mice were fed the HFD or control diet for 16 weeks; at week 10, some of the KO mice on the HFD diet were injected with EX-527 (10 mg/kg every 2 days) until the day of sacrifice. Indeed, SIRT1 inhibition by EX-527 in Suv39h2 mice negated the protection of mice from NASH by Suv39h2 deficiency as evidenced by elevated plasma ALT levels (Fig. 8A) , deteriorated insulin sensitivity (Fig. 8B,C) , and increased plasma/liver lipid contents (Supporting Fig. S11 ). In addition, synthesis of proinflammatory mediators in the liver was significantly upregulated by the administration of EX-527 (Fig. 8D ). In keeping with enhanced hepatic inflammation, EX-527 restored NF-jB acetylation and binding affinity for target promoters in the liver (Supporting Fig. S12 ). EX-527 injection also promoted macrophage skewing toward an M1 phenotype (Fig. 8E) . In all, we conclude that the protective effects of Suv39h2 deficiency in mice might largely derive from SIRT1.
Discussion
Although deemed an essential host defense mechanism pivotal to the survival of organisms, deregulated inflammation in the absence of invading pathogens (dubbed "sterile inflammation") is blamed for a range of human diseases including NASH. (35) We present evidence that the histone H3K9 trimethyltransferase Suv39h2 contributes to NASH pathogenesis in part by promoting the inflammatory response in the liver. Therefore, small-molecule compounds that inhibit Suv39h2 activity (36, 37) could be considered as potential therapeutics in the treatment of NASH.
Peters et al. reported that Suv39h2-deficient mice are viable and exhibit no appreciable defects compared to WT littermates. (15) Indeed, our own characterization of the Suv39h2 mice showed that Suv39h2 deficiency had minimal effects with regard to body weight (Supporting Fig. S1A ) and insulin sensitivity (Fig. 1C) , suggesting that Suv39h2 per se is dispensable for the maintenance of metabolic homeostasis in vivo. Instead, Suv39h2 levels are synonymous with stress cues both in vitro in cultured cells and in vivo in the liver ( Fig. 2; Supporting Fig. S2 and S3). Coincidently, a recent investigation by Hunter et al. demonstrated that Suv39h2 could be up-regulated by acute stress in the hippocampus, paralleling altered learning behavior and H3K9 trimethylation spanning the genome. (38) Benlhabib and Mendelson established a link between Suv39h2 stimulation and surfactant protein A gene repression in response to hypoxic stress in fetal lungs. (39) Collectively, these data portray Suv39h2 as a stress protein bridging H3K9 trimethylation-dependent trans-repression to stimulus-induced pathophysiological proceedings.
Our data show that Suv39h2 may regulate hepatic inflammation through at least two different but not mutually exclusive mechanisms. On the one hand, Suv39h2 represses Sirt1 transcription in hepatocytes, leading to hyperacetylation and thus hyperactivation of NF-jB. On the other hand, Suv39h2 represses Pparg transcription in macrophages, promoting M1 polarization. There are, however, several caveats to this model. First, Suv39h2-mediated SIRT1 trans-repression could take place in macrophages favoring an M1 phenotype. In support of this alternative model, Hah and colleagues have recently shown that SIRT1-deficicent BMDMs more readily differentiated into the M1 subtype when exposed to interferon-gamma. (40) Second, it is not clear at this point how genome-wide transcription, not locus-specific transcription, is regulated by Suv39h2 in the context of NASHassociated hepatic inflammation. Several recent studies exploiting the ChIP sequencing technique have profiled H3K9 trimethylation status across the genome in the brain and found that H3K9Me3-mediated trans-repression may be linked to disorders in cognitive capability. (37, 38) Using H3K9Me3 as a proxy for Suv39h2 activity has its own drawback, however, as its levels are coregulated by both histone methyltransferase and demethylase and therefore do not necessarily reflect the dynamic binding patterns of Suv39h2 on the chromatin. Currently, there is no commercially available Suv39h2 antibody suitable for ChIP sequencing, hampering its thorough functional characterization. It is worthwhile nonetheless to pursue this undertaking in future studies in order to more precisely delineate the role of Suv39h2 in NASH pathogenesis. Finally, we focused our investigation on Suv39h2-dependent H3K9 trimethylation and its consequences in gene expression during NASH pathogenesis. A paradigm in epigenetics holds that histone-modifying enzymes, such as Suv392h2, regulate transcription by catalyzing the modification of both histones and nonhistone factors. (41) Piao et al. identified lysine-specific histone demethylase-1 (LSD1), a histone demethylase, as a substrate for Suv39h2 (42) ; lysine methylation by Suv39h2 stabilizes LSD1 and promotes LSD1-mediated gene transcription. While LSD1 has been implicated in several pathophysiological events germane to NASH, such as lipogenesis (43) (44) (45) it remains unknown how LSD1, downstream of Suv39h2, may contribute to NASH pathogenesis. On a general note, it is warranted to profile nonhistone substrates for Suv39h2 in the liver in order to dissect the histone-dependent and independent functionalities of Suv39h2.
The data presented here should be interpreted with caution, especially because we have exploited a systemic KO model of Suv39h2. One could infer from our results (Supporting Fig. S2 ) that hepatocyte-specific deletion of Suv39h2 might alleviate NASH by promoting fatty acid oxidation and energy expenditure, in addition to dampening NF-jB-mediated inflammation. Alternatively, myeloid-specific Suv39h2 deletion might attenuate NASH by skewing macrophage polarization. The observation that Suv39h2 deletion led to reduced liver fibrosis (Supporting Fig. S3 ) naturally begs the question as to whether Suv39h2 plays a role in the activation of hepatic stellate cells, the major source of fibrogenesis in the liver. To be sure, the behavior of any specific type of cell within the liver is invariably influenced by others through a delicate paracrine network. Whether Suv39h2 functions as a moderator of cell-cell crosstalk in the context of NASH remains unanswered by the present study and deserves further investigation.
We observed that both glucose tolerance and insulin sensitivity were improved in Suv39h2-deficient mice fed a high-fat diet (Fig. 1) ; there are several possible explanations. First, because inflammation is central to the disruption of metabolic homeostasis in the liver and the ensuing insulin resistance, our observation could be construed to reflect the fact that Suv39h2 indirectly impacts hepatic metabolism/insulin sensitivity by modulating the inflammatory profile. Alternatively, our data also suggest that Suv39h2 deficiency might result in increased fatty acid oxidation by upregulating the expression of Cpt1 and Acox1. Therefore, Suv39h2 could be directly involved in the maintenance of metabolic homeostasis in the liver. A third possibility derives from recent reports that demonstrate an involvement of H3K9 trimethylation in adipogenesis, suggesting that Suv39h2 might play a role in regulating adipocyte biology and, by extension, systemic insulin sensitivity. (46, 47) Clearly, this unresolved issue needs to be more thoroughly explored in future studies.
One of the most devastating consequences of NASH is the development of hepatocellular carcinoma. (48) Park and colleagues have recently shown that administration of chaetocin, the H3K9 trimethyltransferase inhibitor, significantly attenuated the growth of hepatoma cells in mice, although it remained undetermined whether the anticancer effects of chaetocin were mediated through Suv39h2. (49) In light of our findings as summarized here, we believe long-term observation of Suv39h2 KO mice placed on the HFD would clarify whether Suv39h2 deficiency can eventually alleviate or even block the transition from NASH to hepatocellular carcinoma. It would certainly lead to a more rationalized decision to target Suv39h2 in the development of novel anti-NASH strategies.
